Hydration protocols to reduce the incidence of contrast-induced nephropathy

Journal of Invasive Cardiology

Volumn 20, Issue 10, 2008, Pages 527-538

  Nikolsky, Eugenia ^a   Mehran, Roxana ^a,b  

^a NewYork Presbyterian Hospital   (United States)

^b CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ASCORBIC ACID; BICARBONATE; CONTRAST MEDIUM; CREATININE; DIATRIZOATE; FUROSEMIDE; IODINE; IODIXANOL; IOHEXOL; IOPAMIDOL; ISOTONIC SOLUTION; MANNITOL; SODIUM CHLORIDE;

ALGORITHM; DIABETES MELLITUS; EUROPE; HEALTH CARE COST; HEART CATHETERIZATION; HOSPITALIZATION; HUMAN; HYDRATION; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY PERFUSION; MORBIDITY; MORTALITY; NEPHROTOXICITY; OSMOLARITY; PERCUTANEOUS CORONARY INTERVENTION; PROGNOSIS; RENAL REPLACEMENT THERAPY; REVIEW; RISK FACTOR; SCORING SYSTEM;

CLINICAL PROTOCOLS; CONTRAST MEDIA; FLUID THERAPY; HUMANS; INCIDENCE; KIDNEY DISEASES; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; UNITED STATES;

EID: 57149087530     PISSN: 10423931     EISSN: 15572501     Source Type: Journal    
DOI: None     Document Type: Review

References (100)

1. American Heart Disease and Stroke Statistics - 2005 Update: Dallas, Texas, American Heart Association; 2005.
2. Togni M, Balmer F, Pfiffner D, et al; Working Group, Interventional Cardiology and Coronary Pathophysiology, European Society of Cardiology. Percutaneous coronary interventions in Europe 1992-2001. Eur Heart J 2004;25:1208-1213.
3. Stevens MA, McCullough PA, Tobin KJ, et al. A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: Results of the PRINCE study: Prevention of Radiocontrast Induced Nephropathy Clinical Evaluation. J Am Coll Cardiol 1999;33:403-411.
4. Guitterez NV, Diaz A, Timmis GC, et al. Determinants of serum creatinine trajectory in acute contrast nephropathy. J Interv Cardiol 2002;15:349-354.
5. McCullough PA, Sandberg KR. Epidemiology of contrast-induced nephropathy. Rev Cardiovasc Med 2003;4 Suppl 5:S3-S9.
6. Parfrey PS, Griffiths SM, Barrett BJ, et al. Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. A prospective controlled study. N Engl J Med 1989;320:143-149.
7. Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis 2002;39:930-936.
8. Levy EM, Viscoli CM, Horwitz RI. The effect of acute renal failure on mortality. A cohort analysis. JAMA 1996; 275:1489-1494.
9. Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002;105:2259-2264.
10. McCullough PA, Wolyn R, Rocher LL, et al. Acute renal failure after coronary intervention: Incidence, risk factors, and relationship to mortality. Am J Med 1997;103:368-375.
11. Gruberg L, Mehran R, Dangas G, et al. Acute renal failure requiring dialysis after percutaneous coronary interventions. Catheter Cardiovasc Interv 2001;52:409-416.
12. Hall KA, Wong RW, Hunter GC, et al. Contrast-induced nephrotoxicity: The effects of vasodilator therapy. J Surg Res 1992;53:317-320.
13. Uddin MA, Rabbani MA, Jafary FH, et al. Contrast nephropathy in high-risk patients undergoing coronary angiography and intervention. J Coll Physicians Surg Pak 2005:791-794.
14. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
15. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-470.
16. Lasser EC, Lyon SG, Berry CC. Reports on contrast media reactions: Analysis of data from reports to the U.S. Food and Drug Administration. Radiology 1997;203:605-610.
17. Lautin EM, Freeman NJ, Schoenfeld AH, et al. Radiocontrast-associated renal dysfunction: Incidence and risk factors. AJR Am J Roentgenol 1991;157:49-58.
18. Nikolsky E, Mehran R, Turcot D, et al. Impact of chronic kidney disease on prognosis of patients with diabetes mellitus treated with percutaneous coronary intervention. Am J Cardiol 2004;94:300-305.
19. Manske CL, Sprafka JM, Strony JT, Wang Y. Contrast nephropathy in azotemic diabetic patients undergoing coronary angiography. Am J Med 1990;89:615-620.
20. Kini AS, Mitre CA, Kim M, et al. A protocol for prevention of radiographic contrast nephropathy during percutaneous coronary intervention: Effect of selective dopamine receptor agonist fenoldopam. Catheter Cardiovasc Interv 2002;55:169-173.
21. Albert SG, Shapiro MJ, Brown WW, et al. Analysis of radiocontrast-induced nephropathy by dual-labeled radionuclide clearance. Invest Radiol 1994;29:618-623.
22. Diaz-Sandoval LJ, Kosowsky BD, Losordo DW. Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial). Am J Cardiol 2002;89:356-358.
23. Rosovsky MA, Rusinek H, Berenstein A, et al. High-dose administration of nonionic contrast media: A retrospective review. Radiology 1996;200:119-122.
24. Kahn JK, Rutherford BD, McConahay DR, et al. High-dose contrast agent administration during complex coronary angioplasty. Am Heart J 1990;120:533-536.
25. Freeman RV, O'Donnell M, Share D, et al; Blue Cross-Blue Shield of Michigan Cardiovascular Consortium (BMC2). Nephropathy requiring dialysis after percutaneous coronary intervention and the critical role of an adjusted contrast dose. Am J Cardiol 2002;90:1068-1073.
26. Khawaja AT, Srinivasan V, Hawa Z, Gradman AH. Reducing radiocontrast use in the cardiac catheterization laboratory - A behavioral modification approach. Qual Manag Health Care 2004;13:188-192.
27. Oymak O. Contrast media induced irreversible acute renal failure in a patient treated with intraperitoneal cisplatin. Clin Nephrol 1995;44:135-136.
28. Mehran R, Aymong ED, Nikolsky E, et al. A Simple Risk Score for Prediction of Contrast-Induced Nephropathy after Percutaneous Coronary Interventions: Development and Initial Validation. J Am Coll Cardiol 2004;44:1393-1399.
29. Nikolsky E, Mehran R, Lasic Z, et al. Low hematocrit predicts contrast-induced nephropathy after percutaneous coronary interventions. Kidney Int. 2005;67:706-713.
30. Rich MW, Crecelius CA. Incidence, risk factors, and clinical course of acute renal insufficiency after cardiac catheterization in patients 70 years of age or older. A prospective study. Arch Intern Med 1990;150:1237-1242.
31. Katholi RE, Taylor GJ, Woods WT, et al. Nephrotoxicity of nonionic low-osmolarity versus ionic high-osmolarity contrast media: A prospective double-blind randomized comparison in human beings. Radiology 1993;186:183-187.
32. Harris KG, Smith TP, Cragg AH, Lemke JH. Nephrotoxicity from contrast material in renal insufficiency: ionic versus nonionic agents. Radiology 1991;179:849-852.
33. Barrett BJ, Carlisle EJ. Metaanalysis of the relative nephrotoxicity of high- and low-osmolarity iodinated contrast media. Radiology 1993;188:171-178.
34. Taliercio CP, Vlietstra RE, Ilstrup DM, et al. A randomized comparison of the nephrotoxicity of iopamidol and diatrizoate in high risk patients undergoing cardiac angiography. J Am Coll Cardiol 1991;17:384-390.
35. Lautin EM, Freeman NJ, Schoenfeld AH, et al. Radiocontrast-associated renal dysfunction: a comparison of lower-osmolality and conventional high-osmolality contrast media. Am J Roentgenol 1991;157:59-65.
36. Rudnick MR, Goldfarb S, Wexler L, et al. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: A randomized trial: The Iohexol Cooperative Study. Kidney Int 1995;47:254-261.
37. Aspelin P, Aubry P, Fransson SG, et al; Nephrotoxicity in High-Risk Patients Study of Iso-Osmolar and Low-Osmolar Non-Ionic Contrast Media Study Investigators. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med 2003;348:491-499.
38. Jo SH, Youn TJ, Koo BK, et al. Renal toxicity evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: the RECOVER study: A randomized controlled trial. J Am Coll Cardiol 2006;48:924-930.
39. Solomon RJ, Natarajan MK, Doucet S, et al. Cardiac Angiography in Renally Impaired Patients (CARE) study: A randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease. Circulation 2007;115:3189-3196.
40. Mehran R. ICON. A prospective, randomized, placebo-controlled trial of ioxaglate versus iodixanol in patients at increased risk for contrast nephropathy. Proceedings of Transcatheter Cardiovascular Therapeutics 2006;3:10.
41. Solomon R, Werner C, Mann D, et al. Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med 1994;331:1416-1420.
42. Weinstein JM, Heyman S, Brezis M. Potential deleterious effect of furosemide in radiocontrast nephropathy. Nephron 1992;62:413-415.
43. Dussol B, Morange S, Loundoun A, et al. A randomized trial of saline hydration to prevent contrast nephropathy in chronic renal failure patients. Nephrol Dial Transplant 2006;21:2120-2126.
44. Weisberg LS, Kurnik PB, Kurnik BR. Risk of radiocontrast nephropathy in patients with and without diabetes mellitus. Kidney Int 1994;45:259-265.
45. Mueller C, Buerkle G, Buettner HJ, et al. Prevention of contrast media-associated nephropathy: Randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med 2002;162:329-336.
46. Merten GJ, Burgess WP, Gray LV, et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA. 2004;291:2328-2334.
47. Briguori C, Airoldi F, D'Andrea D, et al. Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): A randomized comparison of 3 preventive strategies. Circulation 2007;115:1211-1217.
48. Ozcan EE, Guneri S, Akdeniz B, et al. Sodium bicarbonate, N-acetylcysteine, and saline for prevention of radiocontrast-induced nephropathy. A comparison of 3 regimens for protecting contrast-induced nephropathy in patients undergoing coronary procedures. A single-center prospective controlled trial. Am Heart J 2007;154:539-544.
49. Masuda M, Yamada T, Mine T, et al. Comparison of usefulness of sodium bicarbonate versus sodium chloride to prevent contrast-induced nephropathy in patients undergoing an emergent coronary procedure. Am J Cardiol 2007;100:781-786.
50. Brar S. A Randomized Controlled Trial for the Prevention of Contrast Induced Nephropathy with Sodium Bicarbonate vs. Sodium Chloride in Persons Undergoing Coronary Angiography (the Meena Trial). ACC meeting 2007;Abstract 209-209.
51. From AM, Bartholmai BJ, Williams AW, et al. Sodium bicarbonate is associated with an increased incidence of contrast nephropathy: A retrospective cohort study of 7977 patients at Mayo Clinic. Clin J Am Soc Nephrol 2008;3:10-18.
52. Taylor AJ, Hotchkiss D, Morse RW, McCabe J. PREPARED: Preparation for Angiography in Renal Dysfunction: A randomized trial of inpatient vs. outpatient hydration protocols for cardiac catheterization in mild-to-moderate renal dysfunction. Chest 1998;114:1570-1574.
53. Trivedi HS, Moore H, Nasr S, et al. A randomized prospective trial to assess the role of saline hydration on the development of contrast nephrotoxicity. Nephron Clin Pract 2003;93:C29-C34.
54. Krasuski RA, Beard BM, Geoghagan JD, et al. Optimal timing of hydration to erase contrast-associated nephropathy: The OTHER CAN study. J Invasive Cardiol 2003;15:699-702.
55. Bader BD, Berger ED, Heede MB, et al. What is the best hydration regimen to prevent contrast media-induced nephrotoxicity? Clin Nephrol 2004;62:1-7.
56. Clavijo LC, Pinto TL, Kuchulakanti PK, et al. Effect of a rapid intra-arterial infusion of dextrose 5% prior to coronary angiography on frequency of contrast-induced nephropathy in high-risk patients. Am J Cardiol 2006;97:981-983.
57. Vogt B, Ferrari P, Schonholzer C, et al. Prophylactic hemodialysis after radiocontrast media in patients with renal insufficiency is potentially harmful. Am J Med 2001;111:692-698.
58. Lehnert T, Keller E, Gondolf K, et al. Effect of haemodialysis after contrast medium administration in patients with renal insufficiency. Nephrol Dial Transplant 1998;13:358-362.
59. Berger ED, Bader BD, Bosker J, et al. Contrast media-induced kidney failure cannot be prevented by hemodialysis. Dtsch Med Wochenschr 2001;126:162-166.
60. Lee PT, Chou KJ, Liu CP, et al. Renal protection for coronary angiography in advanced renal failure patients by prophylactic hemodialysis. A randomized controlled trial. J Am Coll Cardiol 2007;50:1015-1020.
61. Marenzi G, Marana I, Lauri G, et al.The prevention of radiocontrast-agent-induced nephropathy by hemofiltration. N Engl J Med 2003;349:1333-1340.
62. Marenzi G, Lauri G, Campodonico J, et al. Comparison of two hemofiltration protocols for prevention of contrast-induced nephropathy in high-risk patients. Am J Med 2006;119:155-162.
63. Tepel M, van der Giet M, Schwarzfeld C, et al. Prevention of radiographic-contrastagent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000;343:180-184.
64. Briguori C, Manganelli F, Scarpato P, et al. Acetylcysteine and contrast agent-associated nephrotoxicity. J Am Coll Cardiol 2002;40:298-303.
65. Durham JD, Caputo C, Dokko J, et al. A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney Int 2002;62:2202-2207.
66. Vallero A, Cesano G, Pozzato M, et al. [Contrast nephropathy in cardiac procedures: no advantages with prophylactic use of N-acetylcysteine (NAC)] [Article in Italian] G Ital Nefrol 2002;19:529-533.
67. Webb JG, Pate GE, Humphries KH, et al. A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: Lack of effect. Am Heart J 2004;148:422-429.
68. Coyle LC, Rodriguez A, Jeschke RE, et al. Acetylcysteine In Diabetes (AID): A randomized study of acetylcysteine for the prevention of contrast nephropathy in diabetics. Am Heart J 2006;151:1032.e9-e12.
69. Fung JW, Szeto CC, Chan WW, et al. Effect of N-acetylcysteine for prevention of contrast nephropathy in patients with moderate to severe renal insufficiency: A randomized trial. Am J Kidney Dis 2004;43:801-808.
70. Moore NN, Lapsley M, Norden AG, et al. Does N-acetylcysteine prevent contrast-induced nephropathy during endovascular AAA repair? A randomized controlled pilot study. J Endovasc Ther 2006;13:660-666.
71. Misra D, Leibowitz K, Gowda RM, et al. Role of N-acetylcysteine in prevention of contrast-induced nephropathy after cardiovascular procedures: A meta-analysis. Clin Cardiol 2004;27:607-610.
72. Alonso A, Lau J, Jaber BL, et al. Prevention of radiocontrast nephropathy with N-acetylcysteine in patients with chronic kidney disease: A meta-analysis of randomized, controlled trials. Am J Kidney Dis 2004;43:1-9.
73. Bagshaw SM, Ghali WA. Theophylline for prevention of contrast-induced nephropathy: a systematic review and meta-analysis. Arch Intern Med 2005;165:1087-1093.
74. Kshirsagar AV, Poole C, Mottl A, et al. N-acetylcysteine for the prevention of radiocontrast induced nephropathy: A meta-analysis of prospective controlled trials. J Am Soc Nephrol 2004;15:761-769.
75. Birck R, Krzossok S, Markowetz F, et al. Acetylcysteine for prevention of contrast nephropathy: Meta-analysis. Lancet 2003;362:598-603.
76. Pannu N, Manns B, Lee H, Tonelli M. Systematic review of the impact of N-acetylcysteine on contrast nephropathy. Kidney Int 2004;65:1366-1374.
77. Isenbarger DW, Kent SM, O'Malley PG. Meta-analysis of randomized clinical trials on the usefulness of acetylcysteine for prevention of contrast nephropathy. Am J Cardiol 2003;92:1454-1458.
78. Kelly AM, Dwamena B, Cronin P, et al. Meta-analysis: Effectiveness of drugs for preventing contrast-induced nephropathy. Ann Intern Med 2008;148:284-294.
79. Hoffmann U, Fischereder M, Kruger B, et al. The Value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. J Am Soc Nephrol 2004;15:407-410.
80. Rehman T, Fought J, Solomon R. N-Acetylcysteine Effect on Serum Creatinine and Cystatin C Levels in CKD Patients. Clin J Am Soc Nephrol 2008 Jul 30. [Epub ahead of print].
81. Gare M, Haviv YS, Ben-Yehuda A, et al. The renal effect of low-dose dopamine in high-risk patients undergoing coronary angiography. J Am Coll Cardiol 1999;34:1682-1688.
82. Abizaid AS, Clark CE, Mintz GS, et al. Effects of dopamine and aminophylline on contrast-induced acute renal failure after coronary angioplasty in patients with preexisting renal insufficiency. Am J Cardiol 1999;83:260-263, A265.
83. Allaqaband S, Tumuluri R, Malik AM, et al. Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy. Catheter Cardiovasc Interv 2002;57:279-283.
84. Stone GW, McCullough PA, Tumlin JA, et al. Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. JAMA 2003;290:2284-2291.
85. Tumlin JA, Wang A, Murray PT, Mathur VS. Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontrast dye infusion: A pilot trial in the prevention of contrast nephropathy. Am Heart J 2002;143:894-903.
86. Huber W, Ilgmann K, Page M, et al. Effect of theophylline on contrast material-nephropathy in patients with chronic renal insufficiency: Controlled, randomized, double-blinded study. Radiology 2002;223:772-779.
87. Kolonko A, Wiecek A, Kokot F. The nonselective adenosine antagonist theophylline does prevent renal dysfunction induced by radiographic contrast agents. J Nephrol 1998;11:151-156.
88. Shammas NW, Kapalis MJ, Harris M, et al. Aminophylline does not protect against radiocontrast nephropathy in patients undergoing percutaneous angiographic procedures. J Invasive Cardiol 2001;13:738-740.
89. Erley CM, Duda SH, Rehfuss D, et al. Prevention of radiocontrast-media- induced nephropathy in patients with pre-existing renal insufficiency by hydration in combination with the adenosine antagonist theophylline. Nephrol Dial Transplant 1999;14:1146-1149.
90. Ix JH, McCulloch CE, Chertow GM. Theophylline for the prevention of radiocontrast nephropathy: A meta-analysis. Nephrol Dial Transplant 2004;19:2747-2753.
91. Bagshaw SM, Ghali WA. Theophylline for prevention of contrast-induced nephropathy: A systematic review and meta-analysis. Arch Intern Med 2005;165:1087-1093.
92. Neumayer HH, Junge W, Kufner A, Wenning A. Prevention of radiocontrast-mediainduced nephrotoxicity by the calcium channel blocker nitrendipine: A prospective randomised clinical trial. Nephrol Dial Transplant 1989;4:1030-1036.
93. Khoury Z, Schlicht JR, Como J, et al. The effect of prophylactic nifedipine on renal function in patients administered contrast media. Pharmacotherapy 1995;15:59-65.
94. Spangberg-Viklund B, Berglund J, Nikonoff T, et al. Does prophylactic treatment with felodipine, a calcium antagonist, prevent low-osmolar contrast-induced renal dysfunction in hydrated diabetic and nondiabetic patients with normal or moderately reduced renal function? Scand J Urol Nephrol 1996;30:63-68.
95. Spargias K, Alexopoulos E, Kyrzopoulos S, et al. Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation 2004;110:2837-2842.
96. Kurnik BR, Allgren RL, Genter FC, et al. Prospective study of atrial natriuretic peptide for the prevention of radiocontrast-induced nephropathy. Am J Kidney Dis 1998;31:674-680.
97. Sketch MH Jr, Whelton A, Schollmayer, et al; Prostaglandin E1 Study Group. Prostaglandin E1 Study Group. Prevention of contrast media-induced renal dysfunction with prostaglandin E1: A randomized, double-blind, placebo-controlled study. Am J Ther 2001;8:155-162.
98. Attallah N, Yassine L, Musial J, et al. The potential role of statins in contrast nephropathy. Clin Nephrol 2004;62:273-278.
99. Khanal S, Attallah N, Smith DE, et al. Statin therapy reduces contrast-induced nephropathy: An analysis of contemporary percutaneous interventions. Am J Med 2005;118:843-849.
100. Jo SH, Koo BK, Park JS, et al. Prevention of radiocontrast medium-induced nephropathy using short-term high-dose simvastatin in patients with renal insufficiency undergoing coronary angiography (PROMISS) trial - A randomized controlled study. Am Heart J 2008;155:499;e491-e498.